^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | ERAS-801 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ERASCA GRANTED FDA FAST TRACK DESIGNATION FOR CNS-PENETRANT EGFR INHIBITOR ERAS-801 IN PATIENTS WITH GLIOBLASTOMA
Published date:
05/01/2023
Excerpt:
Erasca...announced the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-801 for the treatment of adult patients with glioblastoma (GBM) with epidermal growth factor receptor (EGFR) gene alterations.
